Deutsche Bank Sees Pharmacyclics (PCYC) Deal as Positive for Abbvie (ABBV)
Tweet Send to a Friend
Deutsche Bank maintained a Buy rating on Abbvie (NYSE: ABBV) with a price target of $80. Shares of Abbvie declined ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
